TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Inclusion Criteria: * Females of non-childbearing potential * Patients with newly diagnosed sputum smear-positive pulmonary MDR-TB infection * Patients must consent to HIV-testing * Patients must be willing to discontinue all TB drugs to allow 7 days washout * Patients having normal weight * Patients are willing to be hospitalized per standard of care. Exclusion Criteria: * Previously having been treated for MDR-TB * Having a significant cardiac arrhythmia that requires medication * For HIV infected patients, having a CD4+ count \< 300 cells/µL * Patients with complicated or severe extrapulmonary manifestations of TB or neurological manifestations of TB * Patients who will require surgical procedure for management of their TB * Evidence of chorioretinitis, optic neuritis, or uveitis at screening * Having had a drug susceptibility test performed prior to screening and being not susceptible to at least 3 of the 5 classes of TB drugs used to treat MDR-TB * Women who are pregnant and/or breastfeeding.